
Just a small daily dose of a popular supplement slashes dementia risk
Researchers analyzed data from 16 major studies involving thousands of people and found that those with low vitamin D levels faced a significantly increased risk of cognitive decline.
The study revealed that people with levels below 20 ng/ml, which is recommended by doctors were about 33 percent more likely to develop dementia or Alzheimer's.
But those with even lower levels, under 10 ng/ml, had an even greater risk, nearly 50 percent higher for dementia and 51 percent higher for Alzheimer's.
Scientists think that low vitamin D might affect the brain by disturbing calcium balance in nerve cells, which can cause brain aging and damage.
Vitamin D helps the brain by removing harmful proteins linked to Alzheimer's, regulating calcium in nerve cells, and protecting brain cells from damage.
Experts say the findings highlight the importance of maintaining healthy vitamin D levels, especially in older adults, who are most vulnerable to both deficiency and cognitive disorders.
While the research doesn't prove that vitamin D supplements will prevent dementia, it strongly suggests that avoiding deficiency could be a crucial step in protecting your brain.
Researchers conducted a meta-analysis, combining data from 16 previous studies, including 12 long-term cohort studies and 4 cross-sectional studies.
The goal was to better understand how vitamin D levels affect the likelihood of cognitive decline.
Alzheimer's disease is one of the most common forms of dementia and mostly affects adults over the age of 65.
It is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate in the brain and damage cells responsible for memory.
Amyloid protein molecules stick together in brain cells, forming clumps called plaques. While tau proteins twist together in fiber-like strands called tangles.
The plaques and tangles block the ability of the brain's neurons to send electrical and chemical signals back and forth.
Over time, this disruption causes permanent damage in the brain that leads to Alzheimer's disease and dementia, causing patients to lose their ability to speak, care for themselves or even respond to the world around them.
About 7million people in the US 65 and older live with the condition and over 100,00 die from it annually.
Leading health experts recommend taking 5,000 IU of vitamin D3 - priced at 20 cents per capsule or $17.99 for 90 - every day
The Alzheimer's Association estimates that by 2050, nearly 13 million Americans will be living with the disease.
While there is no clear cause of the Alzheimer's disease, experts believe it can develop due to genetic mutations and lifestyle choices, such as physical inactivity, unhealthy diet and social isolation.
Additional studies have also shown that Vitamin D provides protection to the brain cells, regulates nerve growth as well as genes important for brain function.
Typically, the body makes vitamin D from direct sunlight on the skin or absorbs it from foods such as milk, egg yolks, beef liver, mushrooms and fatty fishes like salmon and mackerel.
Experts suggest that having a vitamin D level of 20 nanograms/ milliliter (mg/ml) in the blood or higher is adequate for good bone health and anything below 20ng/ml is considered a deficiency.
But despite the critical role it plays, nearly 40 percent of adults are Vitamin D deficient, meaning they are more likely to develop conditions such as osteoporosis (fragile bones), heart problems and Type 2 diabetes.
Additionally, it also aids the function of neurotransmitters such as dopamine and serotonin, which play vital roles in overall mood, cognition and behavior.
Therefore, a deficiency can damage the cell and nerve growth process in the brain which can cause a decline in cognitive abilities, including executive functions like paying attention and processing information.
Brain cell and nerve damage can also contribute to problems in the hippocampus, a brain region crucial for memory formation, which in turn can impair communication between brain regions as well as the brain and rest of the body.
Vitamin D deficiency can manifest in symptoms similar to depression, such as low mood, fatigue and loss of interest in activities - all of which are major contributors to the development of dementia.
However, taking regular vitamin D supplements can help maintain healthy levels of the vitamin in the body which can help protection brain cells, contribute to brain development and maintain cognitive function.
Vitamin D supplements can also help reduce oxidative stress in the brain, described as an imbalance between free radicals and antioxidants in the body that leads to cell damage and various neurological conditions.
Furthermore, Vitamin D has anti-inflammatory properties that can help slow down cognitive decline in older adults.
Apart from capsules, Vitamin D levels in the blood can also be increased by eating consuming foods such as fatty fish and milk while also spending more time in the sun.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medical News Today
28 minutes ago
- Medical News Today
New weekly injection may eliminate need for daily pills in Parkinson's
Parkinson's symptoms develop slowly, most commonly after the age of 50, and include tremor, slowness in movement, limb stiffness, problems with gait and balance, sleep disorders, and mental health with Parkinson's disease have to take several tablets each day to help alleviate their a team of scientists in Australia has developed a weekly injectable treatment for Parkinson's further research proves the injection's safety and efficacy, the long-acting implant could be life changing for people living with Parkinson' disease is the second most common neurodegenerative condition after Alzheimer's Disease. It affects almost 1.1 million people in the United States and more than 10 million worldwide. Of these, 96% are diagnosed after the age of condition occurs when nerve cells in an area of the brain called the substantia nigra stop producing enough of the neurotransmitter dopamine. This leads to a range of symptoms, including:Tremor, or shaking, in hands, arms, legs, jaw, or headMuscle stiffnessSlowness of movementImpaired balance and two main treatments for Parkinson's disease are levodopa (L-dopa), which nerve cells use to make dopamine, and carbidopa, which increases the efficacy of levodopa and helps minimize its side effects. However, people need to take the medications several times a day, which many find difficult to scientists in Australia have developed a long-acting injectable treatment combining the two medications. Because the implant releases the drugs slowly over seven days, people with the condition would no longer have to take multiple tablets every study findings suggest that the injection could be 'a promising system for the delivery of levodopa and carbidopa for Parkinson's patients'.Sneha Mantri, MD MS, Chief Medical Officer for the Parkinson's Foundation, who was not involved in the study, agreed:'If this medication is safe and effective in humans, it could be an alternative for people with [Parkinson's] compared to multiple daily pills.'The findings are published in the journal Drug Delivery and Translational alternative to multiple daily pillsThe injection contains a combination of levodopa (L-dopa) and carbidopa, two drugs used together to treat Parkinson's disease. L-dopa can cross the blood-brain barrier into the central nervous system, where it is converted to dopamine. People with Parkinson's take L-dopa to control the physical symptoms associated with the lack of dopamine prescribe carbidopa in combination with L-dopa to increase its efficacy within the nervous system, and help combat gastrointestinal symptoms, which are a common side effect of two drugs are usually taken in the form of capsules, containing a combination of the drugs in carefully calculated proportions. To reduce the chance of gastrointestinal symptoms, they should be taken with meals. As fat and protein can decrease the absorption of L-dopa, people must avoid high fat or high protein meals when taking the was the injection developed, and how does it work?The newly developed injection also administers a combination of L-dopa and carbidopa in the form of an in-situ their implant, the researchers used two organic polymers and a solvent, in different ratios to achieve the correct rate of drug release. Once the correct ratio was determined, levodopa and carbidopa were added to create the performed several in-vitro tests to determine the effect of pH (acid/alkali balance), how easy it was to inject the implant, how rapidly the implant degraded and the drugs were dispersed, and the effect of the implant on then tested the mechanism ex vivo in leg muscle tissue from a implant performed similarly in vitro and ex vivo, releasing the drugs slowly over several injection into muscle tissue, pores formed on the surface of the implant, through which the drugs diffused into the tissue. Up to 90% of the drug was released over 7 days, and the implant broke down completely within 2 formula that the researchers developed was easy to inject, so they suggest that this could be a:'Promising drug delivery system for Parkinson's patients, which will reduce the dosing frequency in the elderly patients to once-a-week injection.'Potential problems with long-acting injectionsJamie Adams, MD, associate professor of Neurology at the University of Rochester Medical Center, who was not involved in the study, highlighted potential problems with the treatment:'Given fluctuations in Parkinson's symptoms, it may be difficult to determine appropriate dosing for an entire week, and patients may still require oral medications or other therapies. If the weekly injection is dosed too high, that could also be problematic.'And Mantri also raised some issues that will need to be addressed:'Every medication is different, and this type of gel has not been used for [Parkinson's] treatment before. However, many injectable medications carry the risk of injection site reactions (for instance, rash, nodules) related to the delivery method itself.'Promising early development needs further testingThis is an early stage of development of a new mechanism of drug delivery for people with Parkinson's disease. But it has the potential to transform treatment for elderly people with Parkinson' there are several further stages of testing that would need to be undertaken before the implant could be licensed, as Mantri told Medical News Today:'This is a very preliminary study, looking at how the new treatment behaves in the lab. Further testing on animals and then humans will be necessary as it moves forward in drug development.''I would like to see the results of animal testing, as well as human testing, to ensure that this is both safe and effective,' she agreed:'This treatment is still early, and there needs to be human studies, including randomized controlled trials, evaluating safety and efficacy.''A weekly injectable therapy for Parkinson's disease could reduce the burden of frequent medication dosing and may improve quality of life.'— Jamie Adams


Reuters
29 minutes ago
- Reuters
Bristol Myers' drug fails main goal in cancer-related anemia trial
July 18 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia due to a rare bone marrow cancer. The study did not achieve statistically significant results in helping myelofibrosis patients become free from red blood cell transfusions for any 12-week period during the first 24 weeks of treatment. However, more patients receiving Reblozyl saw a reduction in the number of transfusions needed and an increase in hemoglobin levels, a key measure of anemia, the company said. The side effects seen in the trial were similar to those previously reported for Reblozyl. "It is promising to see that Reblozyl led to clinically relevant improvement of anemia for patients with myelofibrosis," said Anne Kerber, head of hematology, oncology, and cell therapy at Bristol Myers. The company remains confident in the treatment's potential to address unmet need, Kerber added. The late-stage trial in myelofibrosis patients tested Reblozyl with a Janus kinase inhibitor drug, a class of medicines that works by slowing down the immune system. Myelofibrosis is a type of cancer, in which the bone marrow becomes scarred and doesn't produce enough healthy blood cells. Reblozyl is already approved for certain types of anemia related to other blood disorders, including myelodysplastic syndromes and beta-thalassemia. Bristol Myers recorded $1.77 billion in global sales of Reblozyl in 2024. Other approved treatments for myelofibrosis-associated anemia include Incyte's (INCY.O), opens new tab Jakafi and British drugmaker GSK's (GSK.L), opens new tab Ojjaara. Reblozyl's failure in the trial might be positive for Disc Medicine (IRON.O), opens new tab, as investors might look favorably at its hepcidin portfolio, given the strength of data and limited treatment options, BMO Capital Markets analysts said.


Daily Mail
29 minutes ago
- Daily Mail
Scientists uncover shocking new link between beloved American drink and deadly strokes
Sweeteners in diet sodas and other popular drinks could raise the risk of deadly strokes, experts warned. Erythritol is a type of sugar alcohol used as a low-calorie sweetener in place of sugar. Your browser does not support iframes.